Galapagos (GB:0JXZ) has released an update.
Galapagos reports significant progress in its cell therapy and small molecule pipeline, with the FDA approval for its ATALANTA-1 study marking a key milestone. The company is focused on accelerating its innovation strategy to address unmet patient needs, backed by a robust financial position with €3.3 billion in cash and investments. Galapagos plans to continue expanding its clinical pipeline and decentralized manufacturing network to support ongoing and future studies.
For further insights into GB:0JXZ stock, check out TipRanks’ Stock Analysis page.
